Novo Nordisk settles US patent fight with Viatris over Ozempic, …
WEB1 day ago · Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo Nordisk, Viatris settle patent dispute over Ozempic, …
WEB1 day ago · Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic.
Amid GLP-1 craze, Novo and Mylan ink patent settlement in …
WEB1 day ago · With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for
WEBN ovo Nordisk (NVO) and Viatris (VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according to Reuters. The two companies informed the U.S....
Novo Nordisk and Mylan Settle Ozempic, Wegovy Patent Battles
WEB1 day ago · Mylan Pharmaceuticals Inc. and Novo Nordisk A/S settled a patent lawsuit and validity challenge linked to Novo’s blockbuster weight-loss and diabetes drugs Ozempic and Wegovy.
Novo Nordisk settles US patent fight with Viatris over ... - AllSides
WEB1 day ago · Oct 7 (Reuters) - Novo Nordisk (NOVOb.CO) and Viatris (VTRS.O) have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Viatris gets USPTO to review Novo Nordisk patent for semaglutide
WEBOct 5, 2023 · Monday, a U.S. Patent and Trademark Office (USPTO) tribunal rejected Viatris' challenge of two Novo patents on the active ingredient for both of the drugs—semaglutide. But Wednesday, the USPTO...
US Patent Office will review Novo Nordisk patent related to …
WEBOct 4 (Reuters) - A U.S. Patent Office tribunal on Wednesday agreed to review the validity of a Novo Nordisk (NOVOb.CO) patent related to its blockbuster diabetes and weight-loss drugs Ozempic...
Viatris makes progress on Ozempic patent challenge
WEBOct 4, 2023 · The U.S. Patent and Trademark Office’s patent trial and appeal board has agreed to review a Novo Nordisk NVO patent covering certain strengths of Ozempic, a Viatris VTRS spokesperson said...
US Patent Office won't review two Novo Nordisk patents for …
WEBOct 2, 2023 · Novo has filed several U.S. patent lawsuits against companies including Pennsylvania-based Viatris that are seeking to market generic versions of the drugs. Viatris has separately asked a...
- Some results have been removed